Latuda® (lurasidone) – Expanded indication
March 6, 2018 - Sunovion announced the FDA approval of Latuda (lurasidone) for monotherapy treatment of pediatric patients (10 to 17 years) with major depressive episode associated with bipolar I disorder (bipolar depression).
Download PDF
